Hecker MRB. Update on monoclonal antibody therapy in the gram-negative sepsis syndrome. J Am Osteopath Assoc 1992;92(8):1017. doi: https://doi.org/10.7556/jaoa.19126.96.36.1997.
Download citation file:
Two multicenter controlled clinical trial~ of genetically engineered monoclonal antibodies directed against endotoxin, a potent mediator of inflammation in the gram-negative sepsis syndrome, were recently reported in the medical literature. One of these antiendotoxin antibodies was derived from a murine (mouse) source, and the other antibody was derived mainly from a human source (nebacumab [negative bacteria human monoclonal antibody D. This article reviews recent literature concerning' the use of these agents in the treatment of gram-negative sepsis syndrome. It also projects economic assessment data regarding the use of nebacumab in the United States.
This PDF is available to Subscribers Only
View Article Abstract & Purchase Options